References
- Torun A, Erdem A, Doğan S, et al. Comparison of the effects of
resistance, aerobic and mixed exercise on athlete’s heart. J Sports
Med Phys Fitness. 2024 Jan;64(1):88-93. doi:
10.23736/S0022-4707.23.15446-6. Epub 2023 Oct 30. PMID: 37902808.
- Berthelot G, Sedeaud A, Marck A, et al. Has Athletic Performance
Reached its Peak? Sports Med. 2015 Sep;45(9):1263-1271. doi:
10.1007/s40279-015-0347-2. PMID: 26094000; PMCID: PMC4536275.
- Jarek A, Wójtowicz M, Kwiatkowska D, et al. The prevalence of
trimetazidine use in athletes in Poland: excretion study after oral
drug administration. Drug Test Anal. 2014 Nov-Dec;6(11-12):1191-6.
doi: 10.1002/dta.1755. Epub 2014 Nov 24. PMID: 25421604.
- Y.J. Li, P.H. Wang, C. Chen, M.H. Zou, D.W. Wang. Improvement of
mechanical heart function by trimetazidine in db/db rat. Acta Pharm.
Sin. 2010, 31, 560.
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez
AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or
Preserved Ejection Fraction. N Engl J Med. 2022 Sep
22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
PMID: 36027570.
- Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV.
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF
[published correction appears in JACC Heart Fail. 2020
Dec;8(12):1057]. JACC Heart Fail. 2020;8(10):800-810.
doi:10.1016/j.jchf.2020.06.020
- Palmi I, Berretta P, Tini A, Ricci G, Marinelli S. The unethicality of
doping in sports. Clin Ter. 2019 Mar-Apr;170(2):e100-e101. doi:
10.7417/CT.2019.2117. PMID: 30993304.
- Jiang H, Jia D, Zhang B, et al. Exercise improves cardiac function and
glucose metabolism in rat with experimental myocardial infarction
through inhibiting HDAC4 and upregulating GLUT1 expression. Basic Res
Cardiol. 2020 Mar 31;115(3):28. doi: 10.1007/s00395-020-0787-1. PMID:
32236769.
- Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan
Across the Spectrum of Ejection Fraction in Heart Failure.
Circulation. 2020 Feb 4;141(5):352-361. doi:
10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17. PMID: 31736342.
- Speakman JR, Selman C. Physical activity and resting metabolic rate.
Proc Nutr Soc. 2003 Aug;62(3):621-34. doi: 10.1079/PNS2003282. PMID:
14692598.
- Celik O, Yildiz BO. Obesity and physical exercise. Minerva Endocrinol
(Torino). 2021 Jun;46(2):131-144. doi: 10.23736/S2724-6507.20.03361-1.
Epub 2020 Nov 19. PMID: 33213121.
- Deacon RM. Measuring motor coordination in rat. J Vis Exp. 2013 May
29;(75):e2609. doi: 10.3791/2609. PMID: 23748408; PMCID: PMC3724562.
- Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and
Neprilysin Inhibition. Circulation. 2016 Mar 15;133(11):1115-24. doi:
10.1161/CIRCULATIONAHA.115.018622. PMID: 26976916; PMCID: PMC4800749.
- Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC.
Sacubitril/valsartan: beyond natriuretic peptides. Heart. 2017
Oct;103(20):1569-1577. doi: 10.1136/heartjnl-2017-311295. Epub 2017
Jul 8. PMID: 28689178.
- Solomon SD, McMurray JJ, Claggett B, et al. Dapagliflozin in heart
failure with mildly reduced or preserved ejection fraction. New
England Journal of Medicine. 2022 Sep 22;387(12):1089-98.
- Salvatore T., Caturano A., Galiero R., et al. Cardiovascular Benefits
from Gliflozins: Effects on Endothelial
Function. Biomedicines. 2021;9:1356.
- Alshnbari A.S., Millar S.A., O’sullivan S.E., Idris I. Effect of
Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A
Systematic Review of Preclinical Studies. Diabetes
Ther. 2020;11:1947–1963. doi: 10.1007/s13300-020-00885-z
- Ma L, Zou R, Shi W, et al. SGLT2 inhibitor dapagliflozin reduces
endothelial dysfunction and microvascular damage during cardiac
ischemia/reperfusion injury through normalizing the
XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 2022 Jun
27;12(11):5034-5050. doi: 10.7150/thno.75121. PMID: 35836807; PMCID:
PMC9274739.
Figure legend: Improvement of median swimming times of the
groups during the experiment
Table 1: Comparison of baseline echocardiography parameters